Latest Corinne Goldsmith Dickinson Center for Multiple Sclerosis Stories
INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp.
Aurora St. Luke's Team Sees Lives Changed for the Better with Plasma Exchange. MILWAUKEE, April 29 /PRNewswire/ -- Researchers at Aurora St.
Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...
Aurora St. Luke's Medical Center Discovers Way to Fight Rare, but Deadly, Side Effect from Drug. MILWAUKEE, Feb. 18 /PRNewswire/ -- Researchers at Aurora St.
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
Acorda Therapeutics, Inc.
Opexa Therapeutics, Inc.
New data from PreCISe, in clinically isolated syndrome patients, have demonstrated that COPAXONE(R) (glatiramer acetate injection) significantly improved neuro-axonal integrity in patients presenting with a first clinical event suggestive of multiple sclerosis (MS) versus patients who received placebo (p=0.03), as measured by proton magnetic resonance spectroscopy (MRS).
Teva Pharmaceutical Industries has announced new positive data from the longest prospective study of treatment to relapsing-remitting multiple sclerosis, which proves robust efficacy and safety of Copaxone.
- Pertaining to the surface or end opposite to the mouth in a radiate animal.